Alaunos Therapeutics Insider Buys 6,515 Shares Amid Bearish Trend—Executives Bet on TCR‑T Cell Therapy Future Confidence Shines Through Market Slide
Insider buying shows confidence in Alaunos Therapeutics’ T‑cell therapy, even as the stock hits a 52‑week low – a potential sign of future upside.
4 minutes to read